XULTOPHY 100/3.6 (insulin degludec/liraglutide)


Drug overview for XULTOPHY 100/3.6 (insulin degludec/liraglutide):

Generic name: insulin degludec/liraglutide (IN-su-lin de-GLOO-dek/LIR-a-GLOO-tide)
Drug class: Intermediate-, Long-acting, and Combination Insulins
Therapeutic class: Endocrine

Insulin degludec is a biosynthetic (rDNA origin), long-acting human insulin Liraglutide, a synthetic, long-acting human glucagon-like peptide-1 (GLP-1) analog. receptor agonist (incretin mimetic), is an antidiabetic agent and antiobesity drug.

Liraglutide (Victoza(R)) is used as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus andalso is used to reduce the risk of major adverse cardiovascular events (i.e., cardiovascular death, nonfatal myocardial infarction (MI), nonfatal stroke) in patients with type 2 diabetes mellitus and established cardiovascular disease. Liraglutide in fixed combination with insulin degludec (insulin degludec/liraglutide;Xultophy(R)) is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Liraglutide (Saxenda(R)) is used for chronic weight management.
DRUG IMAGES
  • XULTOPHY 100 UNIT-3.6MG/ML PEN
    XULTOPHY 100 UNIT-3.6MG/ML PEN
The following indications for XULTOPHY 100/3.6 (insulin degludec/liraglutide) have been approved by the FDA:

Indications:
Type 2 diabetes mellitus


Professional Synonyms:
Adult onset diabetes mellitus
Adult onset diabetes
Adult onset DM
Diabetes mellitus type 2
Diabetes mellitus type II
Ketosis-resistant diabetes mellitus
Ketosis-resistant DM
Maturity onset diabetes mellitus
Maturity onset diabetes
Non-insulin dependent diabetes mellitus
Non-insulin-dependent diabetes mellitus
Type II diabetes mellitus